These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 16818139

  • 1. Malignancy in pediatric transplant recipients.
    Buell JF, Gross TG, Thomas MJ, Neff G, Muthiah C, Alloway R, Ryckman FC, Tiao GM, Woodle ES.
    Semin Pediatr Surg; 2006 Aug; 15(3):179-87. PubMed ID: 16818139
    [Abstract] [Full Text] [Related]

  • 2. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
    Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V.
    Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
    [Abstract] [Full Text] [Related]

  • 3. Posttransplant lymphoproliferative disorder.
    Everly MJ, Bloom RD, Tsai DE, Trofe J.
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [Abstract] [Full Text] [Related]

  • 4. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F, Kunitake H, Laks H, Odim J.
    Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
    [Abstract] [Full Text] [Related]

  • 5. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

  • 6. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 7. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH, Russ GR, Coates PT.
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [Abstract] [Full Text] [Related]

  • 8. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL, Marcus R, Bradley JA.
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [Abstract] [Full Text] [Related]

  • 9. Posttransplant lymphoproliferative diseases.
    Gross TG, Savoldo B, Punnett A.
    Pediatr Clin North Am; 2010 Apr; 57(2):481-503, table of contents. PubMed ID: 20371048
    [Abstract] [Full Text] [Related]

  • 10. Development of lymphoproliferative disease after liver transplantation.
    Marqués E, Jiménez C, Manrique A, Vallejo GH, Clemares M, Ortega P, Moreno E.
    Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
    [Abstract] [Full Text] [Related]

  • 11. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients.
    Libertiny G, Watson CJ, Gray DW, Welsh KI, Morris PJ.
    Br J Surg; 2001 Oct; 88(10):1330-4. PubMed ID: 11578286
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
    Gallego S, Llort A, Gros L, Sanchez de Toledo J, Bueno J, Moreno A, Nieto J, Sanchez de Toledo J.
    Pediatr Transplant; 2010 Feb; 14(1):61-6. PubMed ID: 19344338
    [Abstract] [Full Text] [Related]

  • 13. Malignancy after solid organ transplantation: an overview.
    Zafar SY, Howell DN, Gockerman JP.
    Oncologist; 2008 Jul; 13(7):769-78. PubMed ID: 18614590
    [Abstract] [Full Text] [Related]

  • 14. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J, Kotloff R, Tsai DE.
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [Abstract] [Full Text] [Related]

  • 15. De novo malignances in pediatric organ transplant recipients.
    Penn I.
    Pediatr Transplant; 1998 Feb; 2(1):56-63. PubMed ID: 10084762
    [Abstract] [Full Text] [Related]

  • 16. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
    Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ.
    Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214
    [Abstract] [Full Text] [Related]

  • 17. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
    Hayashida M, Ogita K, Matsuura T, Takahashi Y, Nishimoto Y, Ohga S, Hara T, Soejima Y, Taketomi A, Maehara Y, Kohashi K, Tsuneyoshi M, Taguchi T.
    Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
    [Abstract] [Full Text] [Related]

  • 18. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
    Cornejo A, Bohnenblust M, Harris C, Abrahamian GA.
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
    [Abstract] [Full Text] [Related]

  • 19. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C, Kato T, Gaynor JJ, Ueno T, Selvaggi G, Gordon P, McLaughlin G, Tompson J, Ruiz P, Tzakis A.
    Transplant Proc; 2006 Sep; 38(6):1755-8. PubMed ID: 16908272
    [Abstract] [Full Text] [Related]

  • 20. Controlling the incidence of infection and malignancy by modifying immunosuppression.
    Soulillou JP, Giral M.
    Transplantation; 2001 Dec 27; 72(12 Suppl):S89-93. PubMed ID: 11833147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.